Literature DB >> 23154501

5 years review of periocular basal cell carcinoma and proposed follow-up protocol.

S F Ho1, L Brown, M Bamford, R Sampath, J Burns.   

Abstract

AIM: (1) To investigate the recurrence of periocular basal cell carcinoma (BCC) reported as completely excised on histology. (2) To identify risks associated with recurrence. (3) To recommend a rational follow-up protocol.
METHODS: This is a cohort study by case note review of consecutive patients undergoing excision of periocular BCC between 2000 and 2006 at University Hospitals of Leicester. All lesions were excised with 3 mm clinical margin and the defect reconstructed only after the excision margin was declared clear.
RESULTS: A total of 413 episodes of surgical excision were recorded for 270 patients over the 7-year period of 2000-2006. All of them have 5 years follow-up. Mean age 73.7 (±12.5). In all, 67% were nodular BCC and 45.4% located in the lower eyelid. The main outcome measure was the recurrence rate. None of the patients with primary nodular BCC suffered recurrence. The recurrence rate for primary morphoeaform BCC following complete excision is 3.8%. In total, 8.1% of patients had several lesions simultaneously whereas 7.8% patients had BCC in multiple locations subsequently (metachronous). Three patients who had previously recurrent BCC (rBCC) treated elsewhere or not using this method had orbital/lacrimal drainage system involvement requiring exenteration.
CONCLUSION: We recommend that patients with a single, completely excised primary solid or nodular BCC can be discharged after one 6-monthly review, although they should be instructed to monitor for the development of further lesions. The incidence of recurrence for primary morphoeaform BCC is 3.8% and for rBCC is 3.6% over 5 years and these patients should stay under review for this period.

Entities:  

Mesh:

Year:  2012        PMID: 23154501      PMCID: PMC3545370          DOI: 10.1038/eye.2012.230

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  43 in total

1.  Conventional frozen sections in periocular basal-cell carcinoma: a review of 236 cases.

Authors:  H J Glatt; J J Olson; A M Putterman
Journal:  Ophthalmic Surg       Date:  1992-01

2.  Guidelines of care for basal cell carcinoma. The American Academy of Dermatology Committee on Guidelines of Care.

Authors:  L A Drake; R I Ceilley; R L Cornelison; W A Dobes; W Dorner; R W Goltz; C W Lewis; S J Salasche; M L Turner; G F Graham
Journal:  J Am Acad Dermatol       Date:  1992-01       Impact factor: 11.527

3.  Recurrence rates of treated basal cell carcinomas. Part 1: Overview.

Authors:  M K Silverman; A W Kopf; C M Grin; R S Bart; M J Levenstein
Journal:  J Dermatol Surg Oncol       Date:  1991-09

4.  Frozen section control of excision of eyelid basal cell carcinomas: 8 1/2 years' experience.

Authors:  H J Frank
Journal:  Br J Ophthalmol       Date:  1989-05       Impact factor: 4.638

5.  Clinical characteristics associated with orbital invasion of cutaneous basal cell and squamous cell tumors of the eyelid.

Authors:  G R Howard; J A Nerad; K D Carter; D C Whitaker
Journal:  Am J Ophthalmol       Date:  1992-02-15       Impact factor: 5.258

6.  The necessity of long-term follow up after surgery for basal cell carcinomas of the eyelid.

Authors:  F J Steinkogler; C D Scholda
Journal:  Ophthalmic Surg       Date:  1993-11

Review 7.  Basal cell carcinoma of the eyelid and periocular skin.

Authors:  C E Margo; K Waltz
Journal:  Surv Ophthalmol       Date:  1993 Sep-Oct       Impact factor: 6.048

8.  Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma.

Authors:  D E Rowe; R J Carroll; C L Day
Journal:  J Dermatol Surg Oncol       Date:  1989-04

Review 9.  Biology of basal cell carcinoma (Part I).

Authors:  S J Miller
Journal:  J Am Acad Dermatol       Date:  1991-01       Impact factor: 11.527

10.  Basal cell carcinomas: do they need to be followed up?

Authors:  A J Park; M Strick; J D Watson
Journal:  J R Coll Surg Edinb       Date:  1994-04
View more
  7 in total

1.  Periocular basal cell carcinoma results and surgical outcome during a 5-year period in a larger Danish population.

Authors:  Sveina Björk Karlsdóttir; Simon Johannessen; Nikolaj Carsting Bjerrum; Ulrik Frydkjær-Olsen; Søren Leer Blindbæk; Flemming Møller; Camilla Wellejus
Journal:  BMC Ophthalmol       Date:  2022-06-28       Impact factor: 2.086

2.  Characteristics and Recurrence of Primary Eyelid Basal Cell Carcinoma in Central Spain.

Authors:  Alicia Galindo-Ferreiro; Hortensia Sanchez-Tocino; Cecilia Diez-Montero; Minal Belani-Raju; Raquel García-Sanz; Miguel Diego-Alonso; Ines Llorente-Gonzalez; Patricia Callejo Perez; Rajiv Khandekar; Silvana Schellini
Journal:  J Curr Ophthalmol       Date:  2020-04-30

3.  Retrospective clinicopathological study of 129 cancerous and 18 precancerous lesions of the eyelids in North-Western Greece.

Authors:  Konstantinos Tzoutzos; Anna Batistatou; George Kitsos; Roman Liasko; Dimitrios Stefanou
Journal:  Int Ophthalmol       Date:  2016-05-21       Impact factor: 2.031

4.  The Importance of Frozen Section-Controlled Excision in Recurrent Basal Cell Carcinoma of the Eyelids.

Authors:  Berna Şahan; Ferda Çiftçi; Ferda Özkan; Vildan Öztürk
Journal:  Turk J Ophthalmol       Date:  2016-12-01

Review 5.  Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment.

Authors:  Yingyun Shi; Renbing Jia; Xianqun Fan
Journal:  Onco Targets Ther       Date:  2017-05-08       Impact factor: 4.147

6.  Periocular basal cell carcinoma: recurrence risk factors/when to reoperate?

Authors:  Krzysztof Gąsiorowski; Katarzyna Iwulska; Jan Zapała; Grażyna Wyszyńska-Pawelec
Journal:  Postepy Dermatol Alergol       Date:  2021-01-06       Impact factor: 1.837

7.  Lateral frontal galeal-cutaneous flap for reconstruction after orbital exenteration for advanced periorbital skin cancer

Authors:  Predrag Kovacevic; Jasmina Djordjevic-Jocic; Milan Radojkovic
Journal:  Turk J Med Sci       Date:  2021-02-26       Impact factor: 0.973

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.